KaydedilenlerDerginizi ekleyin

Dergiler / Hipokrat Tıp Dergisi / 2024 / Cilt: 4 Sayı: 3

Bifidobakteri: Kolorektal karsinom için umut vadedici bir koadjuvan

Bifidobacterium: A promising coadjuvant for colorectal carcinoma

Zeynep Yeğin(SİNOP ÜNİVERSİTESİ)0000-0003-4637-0253
Seval Cing Yıldırım(İNÖNÜ ÜNİVERSİTESİ)0000-0001-7163-9512
Sayfa
156–160
Yayın Tarihi
2024-12-20
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Hücre kültürü çalışmaları, hayvan çalışmaları ve bazı yeni klinik çalışmalar Bifidobakterinin terapötik potansiyeline işaret etmektedir.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Batı tarzı beslenme değişiklikleri nedeniyle kolorektal kanser prevalansı hızla artış göstermiştir.
📊
Temel Bulgular & Veri:Bağırsak mikrobiyomunun disbiyozu, inflamasyon ve genotoksisitedeki rollerinden dolayı kanser gelişimini etkilemektedir.
💡
Sonuç & Katkı:Hücre kültürü çalışmaları, hayvan çalışmaları ve bazı yeni klinik çalışmalar Bifidobakterinin terapötik potansiyeline işaret etmektedir.
🔬Tür:Editöre Mektup
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Bifidobakteri · Kolorektal kanser · Apoptozis

Özet

Batı tarzı beslenme değişiklikleri nedeniyle kolorektal kanser prevalansı hızla artış göstermiştir. Bağırsak mikrobiyotasının düzenlenmesi kolorektal kanser tedavisinde ümit verici bir yaklaşım olarak hizmet edebilir. Bağırsak mikrobiyomunun disbiyozu, inflamasyon ve genotoksisitedeki rollerinden dolayı kanser gelişimini etkilemektedir. Hücre kültürü çalışmaları, hayvan çalışmaları ve bazı yeni klinik çalışmalar Bifidobakterinin terapötik potansiyeline işaret etmektedir.

Abstract

Colorectal cancer prevalence has rapidly increased due to dietary changes to Western style. The regulation of the gut microbiota may serve as a promising approach in colorectal cancer management. The dysbiosis of the gut microbiome affects cancer development because of its roles in inflammation and genotoxicity. Cell culture studies, animal studies, and some novel clinical studies refer to the therapeutic potential of Bifidobacterium.

🔖

Bu Makaleye Atıf Yap

Yeğin, Z., Yıldırım, S. C. (2024). Bifidobakteri: Kolorektal karsinom için umut vadedici bir koadjuvan. Hipokrat Tıp Dergisi, Cilt: 4 Sayı: 3, 156–160. https://doi.org/10.58961/hmj.1508458

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (24)

  1. Kim Y, Lee D, Kim D, Cho J, Yang J, Chung M, et al. Inhibition of proliferation in colon cancer cell lines and harmful enzyme activity of colon bacteria by Bifidobacterium adolescentis SPM0212. Arch Pharm Res. 2008;31(4):468–473.
  2. Bahmani S, Azarpira N, Moazamian E. Anti-colon cancer activity of Bifidobacterium metabolites on colon cancer cell line SW742. Turk J Gastroenterol. 2019;30(9):835–842.
  3. Benito I, Encío IJ, Milagro FI, Alfaro M, Martínez-Peñuela A, Barajas M, et al. Microencapsulated Bifidobacterium bifidum and Lactobacillus gasseri in Combination with Quercetin Inhibit Colorectal Cancer Development in ApcMin/+ Mice. Int J Mol Sci. 2021;22(9):4906.
  4. Faghfoori Z, Faghfoori MH, Saber A, Izadi A, Yari Khosroushahi A. Anticancer effects of bifidobacteria on colon cancer cell lines. Cancer Cell Int. 2021;21(1):258.
  5. Yang X, Cao Q, Ma B, Xia Y, Liu M, Tian J, et al. Probiotic powder ameliorates colorectal cancer by regulating Bifidobacterium animalis, Clostridium cocleatum, and immune cell composition. PloS One. 2023;18(3):e0277155.
  6. Yoon Y, Kim G, Jeon BN, Fang S, Park H. Bifidobacterium Strain-Specific Enhances the Efficacy of Cancer Therapeutics in Tumor-Bearing Mice. Cancers (Basel). 2021;13(5):957.
  7. FAO/WHO. Probiotics in food. Health and nutritional properties and guidelines for evaluation. FAO Food and Nutrition Paper. 2006;85.
  8. Lin PY, Li SC, Lin HP, Shih CK. Germinated brown rice combined with Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis inhibits colorectal carcinogenesis in rats. Food Sci Nutr. 2018;7(1):216–224.
  9. Mohammed C, Fuego JP, Garcia KV, Jamil H, Rajesh RY, Escobar AS, et al. A Mini Literature Review of Probiotics: Transforming Gastrointestinal Health Through EvidenceBased Insights. Cureus. 024;16(3):e57055.
  10. Turroni F, van Sinderen D, Ventura M. Genomics and ecological overview of the genus Bifidobacterium. Int J Food Microbiol. 2011;149(1):37-44.
  11. Wong CB, Odamaki T, Xiao JZ. Insights into the reason of Human-Residential Bifidobacteria (HRB) being the natural inhabitants of the human gut and their potential healthpromoting benefits. FEMS Microbiol Rev. 2020;44(3):369-385.
  12. Andresen V, Gschossmann J, Layer P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol Hepatol. 2020;5(7):658-666.
  13. Crovesy L, El-Bacha T, Rosado EL. Modulation of the gut microbiota by probiotics and symbiotics is associated with changes in serum metabolite profile related to a decrease in inflammation and overall benefits to metabolic health: a double-blind randomized controlled clinical trial in women with obesity. Food Funct. 2021;12(5):2161-2170.
  14. Dickerson F, Adamos M, Katsafanas E, Khushalani S, Origoni A, Savage C, et al. Adjunctive probiotic microorganisms to prevent rehospitalization in patients with acute mania: A randomized controlled trial. Bipolar Disord. 2018;20(7):614-621.
  15. Brennan CA, Garrett WS. Fusobacterium nucleatum - symbiont, opportunist and oncobacterium. Nat Rev Microbiol. 2019;17(3):156-166.
  16. Luo K, Zhang Y, Xv C, Ji J, Lou G, Guo X, et al. Fusobacterium nucleatum, the communication with colorectal cancer. Biomed Pharmacother. 2019;116:108988.
  17. Yang Z, Ji G. Fusobacterium nucleatum-positive colorectal cancer. Oncol Lett. 2019;18(2):975-982.
  18. Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, et al. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell. 2017;170(3):548-563.e16.
  19. Jiang SS, Xie YL, Xiao XY, Kang ZR, Lin XL, Zhang L, et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe. 2023;31(5):781-797.e9.
  20. Liang JQ, Zeng Y, Lau EYT, Sun Y, Huang Y, Zhou T, et al. A Probiotic Formula for Modulation of Colorectal Cancer Risk via Reducing CRC-Associated Bacteria. Cells. 2023;12(9):1244.
  21. Lee DK, Jang S, Kim MJ, Kim JH, Chung MJ, Kim KJ, et al. Anti-proliferative effects of Bifidobacterium adolescentis SPM0212 extract on human colon cancer cell lines. BMC Cancer. 2008;8:310.
  22. Mi H, Dong Y, Zhang B, Wang H, Peter CCK, Gao P, et al. Bifidobacterium Infantis Ameliorates Chemotherapy Induced Intestinal Mucositis Via Regulating T Cell Immunity in Colorectal Cancer Rats. Cell Physiol Biochem. 2017;42(6):2330–2341.
  23. Valadez-Bustos N, Escamilla-Silva EM, García-Vázquez FJ, Gallegos-Corona MA, Amaya-Llano SL, Ramos-Gómez M. Oral Administration of Microencapsulated B. Longum BAA999 and Lycopene Modulates IGF-/IGF-1R/IGFBP3 Protein Expressions in a Colorectal Murine Model. Int J Mol Sci. 2019;20(17):4275. Kosumi K, Hamada T, Koh H, Borowsky J, Bullman S, Twombly TS, et al. The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome. Am J Pathol. 2018;188(12):2839–2852.
  24. Zaharuddin L, Mokhtar NM, Muhammad Nawawi KN, Raja Ali RA. A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer. BMC Gastroenterol. 2019;19(1):131. Bajramagic S, Hodzic E, Mulabdic A, Holjan S, Smajlovic SV, Rovcanin A. Usage of Probiotics and its Clinical Significance at Surgically Treated Patients Sufferig from Colorectal Carcinoma. Med Arch. 2019;73(5):316–320.